Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.

An apparent trend emerges revealing that, since the early 2000s, instances of these motifs have been declining, (Fig.

also in 709 other papers

Degradation events and stage of development In our previous work studying biophysical properties of a similar set of clinical-stage antibodies, we noticed a clear trend for molecules in more advanced stage of development having fewer biophysical problems than those in earlier stages (see Figure 3(a ) of Xu et al . 5 ).

also in 19,460 other papers